Enhanced formation of nitric oxide in bladder carcinoma in situ and in BCG treated bladder cancer

Nitric Oxide - Biology and Chemistry

Volumn 15, Issue 4, 2006, Pages 337-343

  Hosseini, Abolfazl ^a   Koskela, Lotta Renström ^a   Ehrén, Ingrid ^a   Aguilar Santelises, Miguel ^a   Sirsjö, Allan ^a   Wiklund, N Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BCG; Bladder cancer; CIS; Nitric oxide

Indexed keywords

BCG VACCINE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

AGED; ARTICLE; BLADDER; BLADDER CANCER; BLADDER CARCINOMA; CANCER STAGING; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN TISSUE; PAPILLOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BCG VACCINE; DNA, COMPLEMENTARY; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; POLYMERASE CHAIN REACTION; RNA, MESSENGER; URINARY BLADDER NEOPLASMS;

MYCOBACTERIUM BOVIS BCG;

EID: 33750475890     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2006.01.007     Document Type: Article

References (31)

1. Wingo P.A., Tong T., and Bolden S. Cancer statistics. Cancer J. Clin. 45 (1995) 8-30
2. Silverman D.T., Hartge P., Morrison A.S., and Devesa S.S. Epidemiololy of bladder cancer. Hematol. Oncol. Clin. North Am. 6 (1992) 1-30
3. Norming U., Nyman C.R., and Tribukait B. Comparative histopathology and deoxyribonucleic acid flow cytometry of random mucosal biopsies in untreated bladder carcinoma. J. Urol. 145 (1991) 1164-1168
4. Wolf H., Rosenkilde Olsen P., and Fischer A. Højgaard, Urothelial atypia concomitant with primary bladder tumor. Scand. J. Urol. Nephrol. 21 (1987) 33-38
5. Wolf H., Melsen F., Pedersen S.E., and Nielsen K.T. Natural history of carcinoma in situ of the urinary bladder. Scand J. Urol. Nephrol. Suppl. 157 (1994) 147-151
6. Lamm D.L. BCG immunotherapy for transitional cell carcinoma of the bladder. Oncology (Huntingt) 9 (1995) 947-952
7. Ratliff T.L., Haaff E.O., and Catalona W.J. Interleukin-2 production during intravesical Bacille Calmette-Guerin therapy for bladder cancer. Clin. Immunol. Immunopathol. 40 (1986) 375-379
8. Fleischmann J.D., Toossi Z., Ellner J.J., Wentworth D.B., Ratcliff T.L., and Imbembo A.L. Urinary interleukins in patients receiving intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer. Cancer 64 (1989) 1447-1454
9. Jackson A.M., Alexandroff A.B., Kelly R.W., Skibinska A., Esuvaranathan K., Prescott S., and Chisholm G.D. Changes in urinary cytokines and soluble intracellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guerin (BCG) immunotherapy. Clin. Exp. Immunol. 99 (1995) 369-375
10. Choi S.C., Oh H.M., Park J.S., Han W.C., Yoon K.H., Kim T.H., Yun K.J., Kim E.C., Nah Y.H., Cha Y.N., Chung H.T., and Jun C.D. Soluble factor from murine bladder tumor-2 cell elevates nitric oxide production in macrophages and enhances the taxol-mediated macrophage cytotoxicity on tumor cells. Cancer Invest. 21 (2003) 708-719
11. Asano K., Chee C.B., Gaston B., Lilly C.M., Gerard C., Drazen J.M., and Stamler J.S. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc. Natl. Acad. Sci. USA 91 (1994) 10089-10093
12. Thomsen L.L., Miles D.W., Happerfield L., Bobrow L.G., Knowles R.G., and Moncada S. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer 72 (1995) 41-44
13. Thomsen L.L., Sargent J.M., Williamson C.J., and Elgie A.W. Nitric oxide synthase activity in fresh cells from ovarian tumor tissue: relationship of enzyme activity with clinical parameters of patients with ovarian cancer. Biochem. Pharmacol. 56 (1998) 1365-1370
14. Gallo O., Masini E., Morbidelli L., Franchi A., Fini-Storchi I., and Vergari W.A. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl. Cancer Inst. 90 (1998) 587-596
15. Radomski M.W., Jenkins D.C., Holmes L., and Moncada S. Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res. 51 (1991) 6073-6078
16. Dong Z., Staroselsky A.H., Qi X., Xie K., and Fidler I.J. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastases in K-1735 murine melanoma cells. Cancer Res. 54 (1994) 789-793
17. Knowles R.G., and Moncada S. Nitric oxide synthase in mammals. Biochem. J. 298 Pt2 (1994) 249-258
18. Morcos E., Jansson O.T., Adolfsson J., Kratz G., and Wiklund N.P. Endogenously formed nitric oxide modulates cell growth in bladder cancer cell lines. Urology 53 (1999) 1252-1257
19. Lundberg J.O.N., Ehrén I., Jansson O., Adolfsson J., Lundberg J.M., Weitzberg E., Alving K., and Wiklund N.P. Elevated nitric oxide in the urinary bladder in infectious and non-infectious cystitis. Urology 48 (1996) 700-702
20. Jansson O.T., Morcos E., Brundin L., Lundberg J.O.N., Adolfsson J., Söderhäll M., and Wiklund N.P. The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer. Br. J. Cancer 78 (1998) 588-592
21. Morcos E., Jansson O.T., Adolfsson J., Ehrén I., and Wiklund N.P. Bacillus Calmette-Guèrin induces long-term local formation of nitric oxide in the urinary bladder via induction of nitric oxide synthase activity urothelial cells. J. Urol. 165 (2001) 678-682
22. Mitropoulos D., Petsis D., Kyroudi-Voulgari A., Koulokossa M., Zervas A., and Dimopoulus C. The effect of intravesical Bacillus Calmette-Guerin instillations on the expression of inducible nitric oxide synthase in humans. Nitric Oxide 13 (2005) 36-41
23. Mostofi F.K., Davis C.J., and Sesterhenn I.A. Histological Typing of Urinary Bladder Tumors. second ed. (1999), Springer Verlag
24. Ehrén I., Hosseini A., Herulf M., Lundberg J.O.N., and Wiklund N.P. Measurement of luminal nitric oxide in bladder inflammation using a silicon balloon catheter- a novel minimally invasive method. Urology 54 (1999) 264-267
25. Austin A.T. The chemistry of the higher oxides of nitrogen as related to the manufacture, storage, and administration of nitrous oxide. Br. J. Anaesth. 39 (1967) 345-350
26. Archer S. Measurements of nitric oxide in biological models. FASEB J. 7 (1993) 349-360
27. Fransén K., Dimberg J., Österström A., Olsson A., Söderkvist P., and Sirsjö A. Nitric oxide synthase 2 mRNA expression in relation to p53 and adenomatous polyposis coli mutations in primary colorectal adenocarcinomas. Surgery 131 (2002) 384-392
28. Swana H.S., Smith S.D., Perrotta P.L., Saito N., Wheeler M.A., and Weiss R.M. Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J. Urol. 161 (1999) 630-634
29. Althausen A.F., Prout Jr G.R., and Daly J.J. Non-invasive papillary carcinoma in the bladder associated with carcinoma in situ. J. Urol. 116 (1976) 575-580
30. Klotz T., Bloch W., Jacobs G., Niggemann S., Engelman U., and Addicks K. Immunolocalization of inducible and constitutive nitric oxide synthases in human bladder cancer. Urology 54 3 (1999) 416-419
31. Hibbs Jr. J.B., Taintor R.R., Vavrin Z., Granger D.L., Drapier J.C., Amber I.J., and Lancaster Jr. J.R. Synthesis of nitric oxide from a terminal guanidino nitrogen atom of l-arginine: a molecular mechanism regulation cellular proliferation that targets intracellular iron. In: Moncada S., and Higgs A. (Eds). Nitric Oxide from l-Arginine: A Bioregulatory System : Proceedings of the Symposium on Biological Importance of Nitric Oxide (1990), Elsevier, Amsterdam 189-223